153 unknown, 126 recruiting, 77 completed, 58 not yet recruiting. 121 Not applicable, 97 Phase 2, 46 Phase 1, 34 Phase 3, 17 Phase 4.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-coated Balloons Versus Drug-eluting Stents for the Treatment of Femoropopliteal In-Stent Restenosis Drug-Coated Balloon-First Strategy, Eluvia Drug-Eluting Stent-First Strategy - Femoropopliteal In-Stent Restenosis (ISR) | Not yet recruiting | Chunshui He | 600 | 2027-01-01 | 2026-09-16 | |
| Vitamin D Status and Its Influencing Factors in Zhejiang Province: A Multicenter Cross-Sectional Study Vitamin D Deficiency | Enrolling by invitation | First Affiliated Hospital of Zhejiang University | 10000 | 2026-10-31 | 2026-10-08 | |
| Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia Tobramycin inhalation solution, 0.9% Sodium Chloride Placebo - Pneumonia, Ventilator-Associated | Phase 4 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 574 | 2026-10-07 | 2026-10-02 |
| Long-term Follow-up of Dexmedetomidine-esketamine and tDCS for Neurocognitive Complications After Surgery Dex-Esk, Placebo, Active tDCS - Older Patients, Surgery | Phase 4 | Not yet recruiting | Peking University First Hospital | 1996 | 2026-10-01 | 2026-10-13 |
| Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD Ruxolitinib treatment, Belumosudil treatment, Belumosudil Switch to Ruxolitinib - Hematopoietic Stem Cell Transplantation (HSCT), cGVHD | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 170 | 2026-10-01 | 2026-08-31 |
| Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery Dex-Esk, Placebo, Active tDCS - Older Patients, Surgery | Phase 4 | Not yet recruiting | Peking University First Hospital | 1996 | 2026-10-01 | 2026-10-13 |
| AI-Based CT Analysis of Coronary Plaque Evolution Coronary Artery Disease | Not yet recruiting | Zhejiang Hospital | 326 | 2026-10-01 | 2026-10-21 | |
| GMPA Versus PPI for Gastric Protection and aGVHD Risk Teprenone, Esomeprazole - Hematopoietic Stem Cell Transplantation (HSCT), aGVHD | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 198 | 2026-09-15 | 2026-08-28 |
| 18F-S2P PET Imaging in the Evaluation of Large Artery Atherosclerosis 18F-S2P - Large-Artery Atherosclerosis (Embolus/Thrombosis) | Not applicable | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 200 | 2026-09-01 | 2026-09-11 |
| SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer SHR-A1811, THPy - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 80 | 2026-09-01 | 2026-08-26 |
| Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy iptacopan - Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT) | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 30 | 2026-08-25 | 2026-08-26 |
| Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma Chidamide, Control Group - T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma | Phase 3 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 132 | 2026-08-15 | 2026-08-19 |
| Safety and Efficacy of Eculizumab in High-risk TA-TMA Eculizumab - Transplant-Associated Thrombotic Microangiopathy (TA-TMA) | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 24 | 2026-07-10 | 2026-07-17 |
| Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donors Single-dose Granulocyte colony-stimulating factor (G-CSF), Divided-dose Granulocyte colony-stimulating factor (G-CSF) - Healthy Hematopoietic Stem Cell Donor, Healthy Allogeneic Hematopoietic Stem Cell Donor | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 560 | 2026-07-10 | 2026-07-15 |
| Efficacy and Mechanism of IPSRT for Bipolar II Disorder Quetiapine (drug), Psychopharmacological treatment - Bipolar Disorder II | Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 216 | 2026-07-01 | 2026-06-17 |
| Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD Trimethoprim-Sulfamethoxazole (TMP-SMX), Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Not applicable | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 630 | 2026-07-01 | 2026-06-24 |
| Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease Finerenone (BAY 94-8862), Placebo - Albuminuria, Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 148 | 2026-07-01 | 2026-06-25 |
| Efgartigimod in Anti-NMDA Receptor Encephalitis. Efgartigimod Alfa - Encephalitis Autoimmune | Phase 2 | Recruiting | Beijing Tongren Hospital | 20 | 2026-06-25 | 2026-09-16 |
| STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump Warfarin (INR 2-3) with placebo, Warfarin (INR 2-3) with aspirin - LVAD (Left Ventricular Assist Device) Thrombosis, LVAD | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 370 | 2026-06-25 | 2026-06-12 |
| HBV Reactivation Prediction Model in Allo-HSCT No Intervention: Observational Cohort - HBV Reactivation, HSCT | Not yet recruiting | Xiao Hui Zhang | 300 | 2026-06-20 | 2026-06-12 |
Showing 20 of 444. Sign in to see all of them.
Consciousness Disorders (18) · Leukemia, Myeloid, Acute (18) · Bipolar Disorder (12) · Peripheral Arterial Disease (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Carcinoma, Non-Small-Cell Lung (11) · Breast Neoplasms (10) · Carcinoma, Hepatocellular (9) · Alzheimer Disease (8) · Acquired Immunodeficiency Syndrome (6) · Depression (6) · Disease (6) · Hematologic Neoplasms (6) · Lymphoma, B-Cell (6) · Multiple Myeloma (6)
venetoclax (12) · Cyclophosphamide (11) · Cytarabine (11) · toripalimab (8) · Neoadjuvant Therapy (7) · Fluorouracil (6) · Granulocyte Colony-Stimulating Factor (6) · Paclitaxel (6) · Cisplatin (5) · Transcranial Magnetic Stimulation (5) · fludarabine (5) · Carboplatin (4) · Epirubicin (4) · Homoharringtonine (4) · Injections (4)
China (398) · Hong Kong (1) · Netherlands (1) · Thailand (1)
Benyan Luo (7) · Yi Luo, M.D. (6) · Benyan Luo, PhD (4) · Lihua Wu, Doctor (4) · Jun-hui Sun, MD,PH.D (3) · Meng Ye, M.D. (3) · Benyan Luo, Ph.D (2) · Benyan Luo, Prof, Dr (2) · Changlin Mei (2) · Changlin Mei, master (2) · Dong-Xin Wang, MD, PhD (2) · Duowu Zou, Doctor (2) · Jian Liu, Master (2) · Jianping Jia, Doctor (2) · Jing Lu, PhD (2)
PMID 26256457, PMID 29472484, PMID 30958370, PMID 31175091, PMID 31235344, PMID 31914229, PMID 31937364, PMID 32881347, PMID 36850008, PMID 37365538, PMID 41671463, PMID 10332016, PMID 12502975, PMID 12547409, PMID 12764261, PMID 12860964, PMID 15535499, PMID 15851849, PMID 16239238, PMID 16916581, PMID 17057569, PMID 17140820, PMID 17645714, PMID 17889125, PMID 18445230, PMID 18580173, PMID 18582931, PMID 18804943, PMID 18847642, PMID 19095497, PMID 19224848, PMID 19347838, PMID 19459814, PMID 19502970, PMID 19857686, PMID 19891819, PMID 20485617, PMID 20541187, PMID 20581422, PMID 20880607, PMID 20930266, PMID 21030019, PMID 21118724, PMID 21251353, PMID 21463757, PMID 21929538, PMID 22123780, PMID 22192663, PMID 22228824, PMID 22340708